Edge Therapeutics Inc Stock Nasdaq
Stocks
US2798701098
Biotechnology & Medical Research
| Market Cap | 67.45M 60.17M 56.06M 51.01M 96.07M 6.5B 96.78M 677M 264M 3.32B 253M 248M 10.66B | P/E 2026 * |
-2.45x | P/E 2027 * | -3.3x |
|---|---|---|---|---|---|
| Enterprise Value | 67.45M 60.17M 56.06M 51.01M 96.07M 6.5B 96.78M 677M 264M 3.32B 253M 248M 10.66B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
80.89% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Edge Therapeutics Inc
| 1 day | -3.76% |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Bedu-Addo
CEO | Chief Executive Officer | 61 | 2019-03-14 |
Kirk Shepard
CTO | Chief Tech/Sci/R&D Officer | 75 | 2024-01-21 |
Spencer Brown
CMP | Compliance Officer | 56 | 2022-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Frank Bedu-Addo
BRD | Director/Board Member | 61 | 2019-03-14 |
Gregory Freitag
BRD | Director/Board Member | 64 | 2019-02-28 |
Stephen Glover
CHM | Chairman | 66 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.76% | +1,662.81% | - | - | 41.89M | |
| +4.16% | +3.42% | +49.37% | +94.17% | 74.16B | |
| -0.37% | -3.81% | +19.75% | +78.12% | 57.39B | |
| +1.63% | -1.61% | +3.83% | +36.89% | 47.64B | |
| +0.50% | +2.94% | +344.62% | +722.17% | 44.29B | |
| +3.05% | -1.80% | +28.78% | +34.51% | 42.5B | |
| +1.00% | -1.46% | +5.17% | +111.90% | 40.71B | |
| -0.54% | +2.41% | +9.31% | +58.85% | 30.97B | |
| +1.56% | +3.75% | +31.34% | +29.14% | 28.53B | |
| +0.76% | -1.45% | -7.44% | -11.12% | 24.34B | |
| Average | +0.80% | -0.14% | +53.86% | +128.29% | 43.39B | |
| Weighted average by Cap. | +1.55% | -0.41% | +58.06% | +137.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -32.9M -29.35M -27.34M -24.88M -46.86M -3.17B -47.21M -330M -129M -1.62B -124M -121M -5.2B | -31.34M -27.96M -26.05M -23.7M -44.64M -3.02B -44.97M -315M -122M -1.54B -118M -115M -4.95B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
